A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Clinical trial NCT02921828 · COMPLETED

Trial details

NCT number: NCT02921828
Sponsor: Celgene
Status: COMPLETED
Study type: OBSERVATIONAL

Multiple Myeloma

Start date: 2015-04-30
Primary completion: 2015-12-10
Enrollment: 1149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.